Selank and Semax for anxiety: what the studies actually show

What did @dr.arturouribe actually say?

The caption, not the spoken transcript, carries most of the substance here. The creator claims Selank and Semax are "péptidos de uso intranasal estudiados en neurociencia" that can "modular ansiedad, enfoque y memoria, sin sedación ni dependencia" — meaning, without sedation or dependency. The actual spoken transcript is garbled and appears to be a transcription error, so this fact-check focuses on the caption's specific claims: that these peptides work through neuroquímica regulation, not simple sedation, and are backed by neuroscience research. Those are claims worth taking seriously, because they are partially grounded in real literature, but the framing around them needs scrutiny.

The caption stops mid-sentence, which means we don't have the full argument. That matters. Incomplete claims can be more misleading than wrong ones, because readers fill in the gaps themselves.

Does the science back this up?

Partially, yes, but with significant caveats that the caption skips entirely. Most of the clinical research on Selank and Semax comes from Russian institutions, with limited independent replication in Western peer-reviewed journals. That is not automatically a reason to dismiss them, but it is a reason to read carefully.

Selank is a synthetic analogue of tuftsin, a naturally occurring immunomodulatory peptide. A 2008 study by Semenova et al. in the Bulletin of Experimental Biology and Medicine found anxiolytic effects in animal models without the sedation profile of benzodiazepines. That "no sedation" claim has some support. Semax, a synthetic ACTH(4-10) analogue, has been studied for its BDNF-upregulating effects. Dolotov et al. (2006, Journal of Neurochemistry) documented BDNF and NGF increases in rat brain tissue following Semax administration. These are real findings. They are also mostly animal and small Russian clinical trial data, which is a very different thing from robust human evidence.

The "sin dependencia" claim is plausible but essentially untested in large human populations. We do not have long-term safety data in humans at scale.

What did they get wrong (or right)?

Credit where it is due: framing anxiety as a neuroquímica regulation issue rather than a moral failing or something to simply "turn off" is a legitimate clinical perspective. The idea that peptides like Selank might modulate GABAergic and serotonergic tone differently than classic anxiolytics is consistent with available mechanistic data. They got that framing right.

What they got wrong, or at least dangerously incomplete: the caption implies these are ready clinical tools with established human evidence. They are not. Selank is approved in Russia as an anxiolytic. It is not FDA-approved. Semax is similarly approved in Russia for neurological conditions. In the US and most of the EU, both exist in a regulatory gray zone, often sold as research chemicals. The creator does not mention this. Omitting that context for 51,600 viewers is a meaningful failure, not a minor oversight.

Also missing: any mention of who should not use these peptides, what interactions might exist, or that intranasal peptide bioavailability in humans is genuinely variable and not well characterized across populations.

What should you actually know?

If you are curious about Selank or Semax, the honest answer is that the mechanistic science is interesting, the human evidence is thin, and the regulatory status in the US makes access complicated and largely unregulated. That combination should make you cautious, not enthusiastic.

BDNF upregulation sounds appealing. So does "no dependence." But those findings come from controlled lab conditions with specific dosing protocols, not from intranasal peptides sourced from compounding pharmacies with variable purity and concentration. A 2021 review by Kolomin et al. in Frontiers in Pharmacology noted that while Semax shows promise for cognitive and mood applications, standardization of formulations and large-scale trials are still lacking.

If anxiety or cognitive issues are affecting your quality of life, there are interventions with far more human evidence behind them: CBT, SSRIs, SNRIs, and in specific cases, established anxiolytics under medical supervision. These peptides may one day earn a stronger evidence base. Right now, they have not.